Clinical Use, Biochemical Response, and Toxicity of Mitotane in Endogenous Cushing Syndrome: A Systematic Review and Evidence Map

Purpose: Mitotane is an adrenolytic and steroidogenesis-modifying drug with an established role in adrenocortical carcinoma (ACC), but it has also been used in patients with difficult-to-control endogenous Cushing syndrome (CS). Its role outside ACC remains uncertain because the available literature includes historical series, referral-center cohorts, combination rescue regimens, pediatric cases, and case reports with differing treatment goals. This systematic review aimed to define the clinical settings in which mitotane has been used for endogenous CS and to summarize biochemical response, time to control, durability of response, treatment exposure, and toxicity, while distinguishing mitotane-dominant therapy from concurrently initiated combination regimens and oncologic treatment of functioning ACC. Methods: PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from inception through 28 June 2026 using the supplied review dataset. Backward and forward citation searching, reference checking of major reviews, and an eligibility re-audit were updated on 7 August 2026. Reports of patients with biochemically confirmed endogenous CS treated therapeutically with oral mitotane were eligible. Cushing disease (CD), ectopic ACTH syndrome (EAS), other ACTH-dependent or adrenal causes of CS, and cortisol-secreting ACC were considered separately. Non-functioning ACC was excluded from CS-specific efficacy analyses. Complete biochemical control was defined preferentially by normalization of urinary free cortisol (UFC) or by the accepted biochemical criterion used in the individual study. Because of substantial clinical and methodological heterogeneity, study-level findings were emphasized and no overall pooled estimate of efficacy, mortality, or toxicity was calculated. Results: Twenty primary reports were included. Among the largest mitotane-dominant datasets, Luton et al. reported remission in 38 of 46 patients with CD treated with mitotane alone, while Donadille et al. reported UFC normalization in 21 of 23 patients with EAS. In the series by Baudry et al., 48 of 67 long-term treated patients with CD achieved remission, with a median time to remission of 6.7 months. Smaller historical series also reported high response proportions. Schteingart et al. described remission in 29 of 36 patients receiving low-dose mitotane together with pituitary irradiation. In contrast, Kamenicky et al. demonstrated rapid biochemical control in severe ACTH-dependent CS when mitotane, metyrapone, and ketoconazole were initiated simultaneously, making it impossible to attribute the early response specifically to mitotane. A 2024 EAS case series also described sustained cortisol control in three patients with advanced pancreatic neuroendocrine tumors. Reported adverse effects included gastrointestinal, neurological, hepatic, lipid, thyroid, gonadal, and adrenal or mineralocorticoid disturbances. Overall certainty of evidence was very low because the available studies were non-randomized, frequently included co-interventions, used heterogeneous outcome definitions, and were subject to substantial selection bias. Conclusion: Mitotane can achieve substantial and sometimes durable control of hypercortisolism in selected patients with endogenous CS, particularly when prolonged adrenal-directed therapy is required and in patients with functioning ACC. Its relatively slow onset limits its use as sole therapy in acute, life-threatening hypercortisolism. The available evidence supports individualized use in specialist practice rather than reliance on a single pooled estimate of efficacy. Prospective multicenter studies with standardized biochemical endpoints, time-to-control measures, therapeutic drug monitoring, and systematic adverse-event reporting are needed.

Authors

Institutions

Publication Details

Journal
Research Square
Published
2026-11-18
DOI
https://doi.org/10.21203/rs.3.rs-11216173/v1
Primary Topic
Pituitary Gland Disorders and Treatments
Type
preprint

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Clinical Use, Biochemical Response, and Toxicity of Mitotane in Endogenous Cushing Syndrome: A Systematic Review and Evidence Map

Rama Walia, Dipika Bansal, Sanjay Kumar Bhadada, Mannuru Venkateswarlu et al.
Research Square
Pituitary Gland Disorders and Treatments
preprint

Clinical Use, Biochemical Response, and Toxicity of Mitotane in Endogenous Cushing Syndrome: A Systematic Review and Evidence Map

Rama Walia, Dipika Bansal, Sanjay Kumar Bhadada, Mannuru Venkateswarlu, Vivek Jha, Pinaki Dutta
preprint en

Abstract

Purpose: Mitotane is an adrenolytic and steroidogenesis-modifying drug with an established role in adrenocortical carcinoma (ACC), but it has also been used in patients with difficult-to-control endogenous Cushing syndrome (CS). Its role outside ACC remains uncertain because the available literature includes historical series, referral-center cohorts, combination rescue regimens, pediatric cases, and case reports with differing treatment goals. This systematic review aimed to define the clinical settings in which mitotane has been used for endogenous CS and to summarize biochemical response, time to control, durability of response, treatment exposure, and toxicity, while distinguishing mitotane-dominant therapy from concurrently initiated combination regimens and oncologic treatment of functioning ACC. Methods: PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from inception through 28 June 2026 using the supplied review dataset. Backward and forward citation searching, reference checking of major reviews, and an eligibility re-audit were updated on 7 August 2026. Reports of patients with biochemically confirmed endogenous CS treated therapeutically with oral mitotane were eligible. Cushing disease (CD), ectopic ACTH syndrome (EAS), other ACTH-dependent or adrenal causes of CS, and cortisol-secreting ACC were considered separately. Non-functioning ACC was excluded from CS-specific efficacy analyses. Complete biochemical control was defined preferentially by normalization of urinary free cortisol (UFC) or by the accepted biochemical criterion used in the individual study. Because of substantial clinical and methodological heterogeneity, study-level findings were emphasized and no overall pooled estimate of efficacy, mortality, or toxicity was calculated. Results: Twenty primary reports were included. Among the largest mitotane-dominant datasets, Luton et al. reported remission in 38 of 46 patients with CD treated with mitotane alone, while Donadille et al. reported UFC normalization in 21 of 23 patients with EAS. In the series by Baudry et al., 48 of 67 long-term treated patients with CD achieved remission, with a median time to remission of 6.7 months. Smaller historical series also reported high response proportions. Schteingart et al. described remission in 29 of 36 patients receiving low-dose mitotane together with pituitary irradiation. In contrast, Kamenicky et al. demonstrated rapid biochemical control in severe ACTH-dependent CS when mitotane, metyrapone, and ketoconazole were initiated simultaneously, making it impossible to attribute the early response specifically to mitotane. A 2024 EAS case series also described sustained cortisol control in three patients with advanced pancreatic neuroendocrine tumors. Reported adverse effects included gastrointestinal, neurological, hepatic, lipid, thyroid, gonadal, and adrenal or mineralocorticoid disturbances. Overall certainty of evidence was very low because the available studies were non-randomized, frequently included co-interventions, used heterogeneous outcome definitions, and were subject to substantial selection bias. Conclusion: Mitotane can achieve substantial and sometimes durable control of hypercortisolism in selected patients with endogenous CS, particularly when prolonged adrenal-directed therapy is required and in patients with functioning ACC. Its relatively slow onset limits its use as sole therapy in acute, life-threatening hypercortisolism. The available evidence supports individualized use in specialist practice rather than reliance on a single pooled estimate of efficacy. Prospective multicenter studies with standardized biochemical endpoints, time-to-control measures, therapeutic drug monitoring, and systematic adverse-event reporting are needed.

Research Square
National Institute of Pharmaceutical Education and Research (IN), National Institute of Pharmaceutical Education and Research (IN), National Institute of Pharmaceutical Education and Research (IN), National Institute of Pharmaceutical Education and Research (IN), National Institute of Pharmaceutical Education and Research (IN), National Institute of Pharmaceutical Education and Research (IN), Post Graduate Institute of Medical Education and Research (IN)
Postgraduate Institute of Medical Education and Research, Chandigarh
Good health and well-being
Pituitary Gland Disorders and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon